Discover why controlled O2 levels are critically important in cell-based research in our latest webinar.
Researchers at Wake Forest School of Medicine say that they have identified a set of new genetic bio markers.
These markers could potentially lead to new personalized treatments for lung cancer.
TCR2 Therapeutics Inc., a clinical stage-cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer is expanding to a facility in Rockville, Maryland.
The expansion will accelerate the development of its lead program, Gavo-Cell in 2021.
Discover the next interview in the series as Dr. Ox continues to interview leading scientists.
Featuring Hans Clevers of Hubrecht Institute, learn more about his role in Developmental Biology and Stem Cell Research.
Last month, the FDA approved Abecma as the first B-cell maturation antigen (BCMA)- directed chimeric antigen receptor T-cell immunotherapy for patients with relapsed or refractory multiple myeloma.
Encouraging findings, led by scientists at Washington School of Medicine found that a new nanoparticle-based system allows flu vaccines to be assembled in a Lego like manor.
By simplifying the construction of multivalent vaccines, it is also possible to arrange diverse antigens.
In the case of Multiple Sclerosis and other autoimmune conditions, our immune defences turn on the body rather than protect it.
T cells become activated in the lymph system and then enter the CNS through blood vessels. Once through, they then release chemicals, activating B cells that cause the damage associated with the condition.
Out of the box thinking, inside the box - from research to GMP.
Learn more about Baker Ruskinn’s Physiological Oxygen ISO Class 3 Workstations!
AeroPROTECT 360° is a truly versatile containment unit for Laboratory Automation.
Complete with Baker’s exclusive technology, you are able to maximize product protection whilst meeting NSF International Standard 49.
Affibody and Inmagene Pharmaceuticals reported that the FDA has cleared the interleukin-17 blocker known as Izokibep.
This means that Phase 2 clinical development into non-infectious intermediate, posterior and pan-uveitis can commence.
Sign up to our monthly newsletter to stay up to date on everything that’s going on at Baker.